These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 4860445)

  • 1. Differential binding to the hydrophobic bonding region of T2 phage induced, Escherichia coli B, and pigeon liver dihydrofolic reductases.
    Baker BR
    J Med Chem; 1967 Sep; 10(5):912-7. PubMed ID: 4860445
    [No Abstract]   [Full Text] [Related]  

  • 2. Irreversible enzyme inhibitors. CV. Differential irreversible inhibition of vertebrate dihydrofolic reductases by derivatives of 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazines substituted with a terminal sulfonyl fluoride.
    Baker BR; Lourens GJ
    J Med Chem; 1967 Nov; 10(6):1113-22. PubMed ID: 6056040
    [No Abstract]   [Full Text] [Related]  

  • 3. Dihydrofolate reductases of Escherichia coli and bacteriophage Tr. A spectrofluorometric study.
    Erickson JS; Mathews CK
    Biochemistry; 1973 Jan; 12(3):372-80. PubMed ID: 4405201
    [No Abstract]   [Full Text] [Related]  

  • 4. Irreversible enzyme inhibitors. CX. Candidate irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine. IV.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):34-7. PubMed ID: 5237172
    [No Abstract]   [Full Text] [Related]  

  • 5. Irreversible enzyme inhibitors. CIX. Candidate irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine. 3.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):26-33. PubMed ID: 5237171
    [No Abstract]   [Full Text] [Related]  

  • 6. Irreversible enzyme inhibitors. CXII. Active-site-directed irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine substituted with a terminal sulfonyl fluoride. II.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):38-41. PubMed ID: 5237173
    [No Abstract]   [Full Text] [Related]  

  • 7. Irreversible enzyme inhibitors. CXVII. Hydrophobic bonding to dihydrofolic reductase. XI. Comparison of the enzyme from Walker 256, rat liver, and L1210 mouse leukemia.
    Baker BR
    J Med Chem; 1968 May; 11(3):483-6. PubMed ID: 5241406
    [No Abstract]   [Full Text] [Related]  

  • 8. T4 bacteriophage-specific dihydrofolate reductase: purification to homogeneity by affinity chromatography.
    Erickson JS; Mathews CK
    Biochem Biophys Res Commun; 1971 Jun; 43(5):1164-70. PubMed ID: 4936128
    [No Abstract]   [Full Text] [Related]  

  • 9. Folate inhibitors: a structure-activity analysis using linear modeling.
    Hansch C
    Ann N Y Acad Sci; 1971 Nov; 186():235-47. PubMed ID: 4943575
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitor binding analysis of dihydrofolate reductases from various species.
    Burchall JJ; Hitchings GH
    Mol Pharmacol; 1965 Sep; 1(2):126-36. PubMed ID: 4378654
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparative biochemistry of dihydrofolate reductase.
    Burchall JJ
    Ann N Y Acad Sci; 1971 Nov; 186():143-52. PubMed ID: 4943573
    [No Abstract]   [Full Text] [Related]  

  • 12. Irreversible enzyme inhibitors. 133. Studies on differential irreversible inhibition of dihydrofolic reductase from three strains of L1210 leukemia, liver, spleen, and intestine of the mouse.
    Baker BR; Lourens GJ; Meyer RB; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):67-73. PubMed ID: 5763043
    [No Abstract]   [Full Text] [Related]  

  • 13. Thermodynamic study of folate analogue binding to dihydrofolate reductases from different species.
    Sasso S; Gilli R; Lopez C; Sari JC; Briand C
    Adv Exp Med Biol; 1993; 338():521-4. PubMed ID: 8304171
    [No Abstract]   [Full Text] [Related]  

  • 14. Mechanism of inhibition of dihydrofolate reductases from bacterial and vertebrate sources by various classes of folate analogues.
    Stone SR; Morrison JF
    Biochim Biophys Acta; 1986 Feb; 869(3):275-85. PubMed ID: 3511964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isolation and characterization of mutants of bacteriophage T4 resistant to folate analogs.
    Johnson JR; Hall DH
    Virology; 1973 Jun; 53(2):413-26. PubMed ID: 4576345
    [No Abstract]   [Full Text] [Related]  

  • 16. Irreversible enzyme inhibitors. 118. Hydrophobic bonding to dihydrofolic reductase. XII. Further comparisons with the enzyme from Walker 256 rat tumor and rat liver.
    Baker BR; Johnson MA
    J Med Chem; 1968 May; 11(3):486-8. PubMed ID: 5241407
    [No Abstract]   [Full Text] [Related]  

  • 17. Plasmodium berghei dihydrofolate reductase. Isolation, properties, and inhibition by antifolates.
    Ferone R; Burchall JJ; Hitchings GH
    Mol Pharmacol; 1969 Jan; 5(1):49-59. PubMed ID: 4392112
    [No Abstract]   [Full Text] [Related]  

  • 18. Irreversible enzyme inhibitors. LXXXVI. Hydrophobic bonding to dihydrofolic reductase. 8. Substituted-1-aryl-4,6-diamino-1,2-dihydro-2,2-dimethyl-s-triazines.
    Baker BR; Ho BT; Lourens GJ
    J Pharm Sci; 1967 Jun; 56(6):737-42. PubMed ID: 5231391
    [No Abstract]   [Full Text] [Related]  

  • 19. Ligand binding studies, preliminary structure-activity relationship and detailed mechanistic characterization of 1-phenyl-6,6-dimethyl-1,3,5-triazine-2,4-diamine derivatives as inhibitors of Escherichia coli dihydrofolate reductase.
    Srinivasan B; Tonddast-Navaei S; Skolnick J
    Eur J Med Chem; 2015 Oct; 103():600-14. PubMed ID: 26414808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dihydrofolic reductase in human blood cells. I. Techniques for the study of enzyme activity and intracellular amethopterin content.
    Martelli MF; Tonato M; Grignani F
    Enzymol Biol Clin (Basel); 1967; 8(5):353-62. PubMed ID: 4383611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.